pengguizi 2016-01-06 08:40 IP:广州
求他克莫司片缓释胶囊大生产工艺及相关研究   [更多]
悬赏:
悬赏
¥5000.00
载入中...
2076785531 2015-12-29 09:32 IP:广州
需要完整的甲苯磺酸妥舒沙星中试(公斤级)工艺;完整工艺杂质研究、初步的质控标准。   [更多]
悬赏:
悬赏
¥1000.00
载入中...
zhouxixi 2015-08-19 15:35 IP:重庆
在合理合法的范围内   [更多]
悬赏:
悬赏
¥3000.00
载入中...
dahan2000 2015-07-29 11:56 IP:天津
成本,生产周期,产品质量,工艺规模请列出。   [更多]
悬赏:
悬赏
¥0.00
载入中...
xiaomaguohe 2015-05-25 10:20 IP:济南
合理的大生产工艺即可或中试工艺   [更多]
悬赏:
悬赏
¥20000.00
载入中...
lyj19721101 2015-04-27 17:16 IP:马鞍山
基因治疗的概念出现在几十年前,当研究人员推测,人类疾病可以通过精确使用一种技术引入外来DNA来解决遗传缺陷和疾病症状。近年来,基因治疗的进步已经涉足治疗遗传疾病,癌症,神经退行性疾病等各领域。遗传性疾病如色素性视网膜炎等少数眼部疾病的基因也可以如此治疗。公司征集一种在人类眼部组织定性和定量(半)测量体内基因表达的方法。 具体如下https://www.innocentive.com/ar/challenge/9933643 The concept of gene therapy arose decades ago, when researchers postulated that human diseases could be treated by using a technique to introduce foreign DNA to correct genetic defects and disease phenotypes. In recent years, advances in gene therapy have been documented in the treatment of genetic disorders, cancer, and neurodegenerative diseases. Inherited diseases such as retinitis pigmentosa are among a handful of ocular diseases that are amenable to gene therapy. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933643 Challenge Overview The number of clinical trials for gene therapy to treat ocular disorders is on the rise. Inherited diseases such as retinitis pigmentosa among others are thought to be good candidates for targeted treatment. Currently, there is no method in humans to determine the level or geographic location of transgene expression following administration of gene therapy for diseases of the eye, specifically the retina. The Seeker desires solutions that will both qualitatively and (semi-) quantitatively measure in vivo gene expression in human ocular tissues. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 20, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a   [更多]
悬赏:
悬赏
¥46000.00
载入中...
happyjingjing 2015-04-21 09:53 IP:重庆
具体要求: 要求工艺成熟,具有成本优势.   [更多]
悬赏:
悬赏
¥0.00
载入中...
lyj19721101 2015-04-03 15:04 IP:马鞍山
我们需要设计自动崩解控制器用于靶向给药。自动崩解控制器,一旦触发,应该可以在温和条件(生理)下使药物分子的释放并激活。这个我们可以参考数量有限的文献中描述“self-immolative”(自动分解或自毁)连接器,但我们提出的自动崩解控制器不是这样的装置。具体链接为https://www.innocentive.com/ar/challenge/9933733,具体如下: Design of A Self-Cleaving Linker For Targeted Drug Delivery TAGS: Physical Sciences, Novel Molecules, Chemistry, Life Sciences, Theoretical-IP Transfer AWARD: $25,000 USD | DEADLINE: 4/27/15 | ACTIVE SOLVERS: 165 | POSTED: 3/26/15 The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of “self-immolative” linkers are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933733 Challenge Overview The Seeker desires the design of a novel self-cleaving linker for use in targeted drug delivery. The self-cleaving linker, once triggered, should allow for the release of molecule(s) of interest under mild (physiological) conditions. A limited number of such “self-immolative” linkers, based upon an elimination to generate a quinone methide, or utilizing a 5 or 6 member ring cyclization, are well described in the literature and are specifically excluded from this Challenge. The Seeker specifically encourages synthetic chemists to consider this Challenge even if they do not have medicinal chemistry knowledge. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property   [更多]
悬赏:
悬赏
¥25000.00
载入中...
5334370 2015-03-31 09:12 IP:武汉
标题:重金求购更昔洛韦标准提高 详细要求: 需求名称:更昔洛韦标准提高 具体要求:招标报价,价格面议 要求时间:请在2015年4月之前 交稿方式:直接点击交稿在线交稿就是了,我会每天过来看的,谢谢各位药智的战友们   [更多]
悬赏:
悬赏
¥0.00
载入中...
tania_zll_417 2015-03-25 08:24 IP:台州
中文别名: 7-溴-1-环丙基-8-二氟甲氧基-1,4-二氢-4-氧代喹啉-3-羧酸乙酯 英文名称: 3-Quinolinecarboxylicacid, 7-bromo-1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxo-, ethyl ester; Ethyl7-bromo-1-cyclopropyl-8-(difluoromethoxy)-1,4-dihydro-4-oxoquinoline-3-carboxylate;Ethyl7-bromo-1-cyclopropyl-8-difluoromethoxy-4-oxo-1,4-dihyd... CAS No.: 194805-07-7 EINECS号: 分子式: C16H14 Br F2 N O4   [更多]
悬赏:
悬赏
¥0.00
载入中...
发布需求,坐等药智客上门
  • 安全可靠,先验收再正式付款
  • 性价比超高,节省一半费用
  • 80%的需求得到了圆满解决
立即发布需求

推荐任务